SIGNAL Trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1042474

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

IgA nephropathy is one of the most common causes of kidney failure in Australia and around the world, but there are currently no specific treatments proven to prevent kidney failure. The SIGNAL trial, jointly led by Australian and Chinese researchers, will bring together leading experts from around the world to reliably ascertain the effects of steroid therapy in this condition, and could potentially prevent many people from developing kidney failure in the future.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $2,681,619.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

IgA nephropathy | adverse effects | clinical trial | kidney failure | steroids

Related Links